explore -WSS

explore

author：entertainment 2025-09-03 07:49:02 - browse：71

Adam's take main illustration — Molly Ferguson/STAT

CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly acquired and costly treatment for myelofibrosis. I suspect the Swiss pharma giant’s previously stated plan to submit a marketing application to the Food and Drug Administration this year has been blocked.

I’m not just speculating wildly. It’s looking increasingly likely that the $3 billion purchase of MorphoSys to acquire pelabresib — a deal pushed hard by top Novartis executive strategist Ronny Gal over some internal dissent — has run into serious trouble just days after the closing.

On Sunday evening, Novartis Chief Medical Officer Shreeram Aradhye, speaking at the company’s ASCO investor event here in Chicago, offered this response to an analyst who asked about pelabresib.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： ER docs worry over extreme heat as a 'mass casualty event'

WSS

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

Multiple sclerosis has subtypes with different best treatments: study

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

Scientific mystery highlights the blind spots in genomics databases

Oral obesity drug from Viking Therapeutics hits key early target

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

leisure time

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

What Henrietta Lacks settlement says about racism in medicine

How one medical school became remarkably diverse

Oral obesity drug from Viking Therapeutics hits key early target

Malaria cases in Florida and Texas: Here’s what you need to know

First Opinion on colorectal cancer screening: letter and response

Jerome Adams on the need for new antivirals for Covid

White House drug shortage group privately met with industry

New air purifier tech could be key to improving indoor air quality

White House drug shortage group privately met with industry

knowledge

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

What Mike Pence has said that could be used in a Donald Trump trial

Harvard scientists, with Google, unveil the most detailed brain map ever

Harvard scientists, with Google, unveil the most detailed brain map ever

UnitedHealth, in a surprise, takes aim at Steward’s physician group

UnitedHealth, in a surprise, takes aim at Steward’s physician group

leisure time

entertainment

hotspot

focus